The Asia-Pacific injection pen market is anticipated to grow at a CAGR of 8.1% over the forecast period. The key factors that drive the growth of the injection pen industry in the Asia-Pacific region include the huge population and a large pool of diabetic patients in the region. As per the World Bank 2020, China is the second-largest economy after the US and has the world’s largest population of approximately 1.4 billion, followed by India of approximately 1.3 billion.
A full report of Asia-Pacific Injection Pen Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-injection-pen-market
Both economies hold nearly 40.0% of the total world population share. The United Nations Population Division projects that India’s population aged 50 years and older will reach 34.0% by 2050. Whereas, Beijing State Council Information Office projected that China’s aged population (above 60 years old) will reach 255 million by 2020. With a rise in the population along with the age dynamics, there is an increased chance of incidences of diabetes in the Asia-Pacific, which is expected to increase the market growth.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-injection-pen-market
Market Coverage
- Market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type, By Disorder Type
- Regions Covered- Asia-Pacific
- Competitive Landscape- Mylan N.V., Eli Lily & Co., F. Hoffmann-La Roche Ltd., Pfizer Inc., and GlaxoSmithKline Plc
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in the base year?
- Which segment will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Asia-Pacific Injection Pen Market – Segmentation
By Type
- Reusable
- Disposable
By Disorder Type
- Autoimmune Disorders
- Hormonal Disorders
- Orphan Diseases
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
